Study of the Role of Cytosolic Phospholipase A2 Alpha in Eicosanoid Generation and Thymocyte Maturation in the Thymus

Matthieu Rousseau1, Gajendra S. Naika2, Jean Perron3, Frederic Jacques3, Michael H. Gelb2, Eric Boilard1 *

1 Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Faculté de Médecine de l’Université Laval, Québec, QC, Canada, 2 Department of Chemistry, University of Washington, Seattle, WA, the United States of America, 3 Centre de Recherche du Centre Hospitalier Universitaire de Québec, Faculté de Médecine de l’Université Laval, Québec, QC, Canada

* eric.boilard@crchuq.ulaval.ca

Abstract

The thymus is a primary lymphoid organ, home of maturation and selection of thymocytes for generation of functional T-cells. Multiple factors are involved throughout the different stages of the maturation process to tightly regulate T-cell production. The metabolism of arachidonic acid by cyclooxygenases, lipoxygenases and specific isomerases generates eicosanoids, lipid mediators capable of triggering cellular responses. In this study, we determined the profile of expression of the eicosanoids present in the mouse thymus at different stages of thymocyte development. As the group IVA cytosolic phospholipase A2 (cPLA2α) catalyzes the hydrolysis of phospholipids, thereby generating arachidonic acid, we further verified its contribution by including cPLA2α deficient mice to our investigations. We found that a vast array of eicosanoids is expressed in the thymus, which expression is substantially modulated through thymocyte development. The cPLA2α was dispensable in the generation of most eicosanoids in the thymus and consistently, the ablation of the cPLA2α gene in mouse thymus and the culture of thymuses from human newborns in presence of the cPLA2α inhibitor pyrrophenone did not impact thymocyte maturation. This study provides information on the eicosanoid repertoire present during thymocyte development and suggests that thymocyte maturation can occur independently of cPLA2α.

Introduction

The thymus has a central role in the immune system as it supports the development, the differentiation and the selection of T-cells [1–3]. Thymic development of the T-cell precursors is finely regulated. Firstly, the T-cell precursors originating from the bone marrow enter in the thymus through the cortex. These immature T-cells, called thymocytes, differently express the T-cell receptor (TCR) co-receptors CD4 and CD8 at their surface, an indication of the T-cell maturation state. Owing to the lack of expression of CD4 and CD8 immediately after their
entrance in the cortex, the most immature T-cells are identified as double negative (DN) thy-
mocytes (CD4-/CD8-). Secondly, after a productive rearrangement of the TCR β locus and ex-
pression of pre-TCR, thymocytes initiate the expression of CD4 and CD8 and are recognized
as double positive (DP) thymocytes. Finally, the DP thymocytes undergo positive and negative
selections driven by dendritic cells, cortical and medullar thymic epithelial cells. These two se-
lection processes eliminate by apoptosis the thymocytes considered as useless and self-reactive.
The positively selected thymocytes then migrate to the medulla and egress from the thymus as
single positive (SP) thymocytes (i.e. CD4+/CD8- and CD4-/CD8+).

Multiple factors tightly regulate the formation of T-cells throughout the different stages of
the maturation process. Cytokines and chemokines for instance are involved in thymocyte sur-
vival, differentiation, selection and guidance through the thymus [3, 4]. Eicosanoids are lipid
mediators derived from fatty acids, such as arachidonic acid (AA), and are synthesized primar-
ily by three classes of enzymes, cyclooxygenases 1 (COX-1) or 2 (COX-2), lipoxygenases
(LOX) and cytochrome P450 mono-oxygenases. The role of eicosanoids in regulation of im-
munity is well documented. For example, prostaglandin E2 (PGE2), prostanoid formed via the
concerted action of cyclooxygenases (COX-1 and COX-2) and PGE synthase, induces Th2 po-
larization by modulating cytokine production of antigen presenting cells and T-cells [5]. PGE2
inhibits the production of interleukin (IL)-2, IL-12 and interferon-γ by monocytes, T-cells and
antigen presenting cells, it decreases the responsiveness of IL-12 receptors by peripheral blood
mononuclear cells and T-cells and increases T-cell production of IL-4, IL-5, and IL-10 [5–9].
Alternatively, PGE2 has also a role in the differentiation of Th17-cells, and nanomolar concen-
trations of this eicosanoid suffice to promote Th1 differentiation, whereas higher concentra-
tions of PGE2 suppress this process [10–13]. Furthermore, it was shown that PGE2 suppresses
allergic reactions through the PGE2 receptor 3 (EP3) [14] and promotes induction of FOXP3+
CD4+ CD25+ adaptive regulatory T-cells that regulate immune responses [15–17]. Finally,
PGE2 supports the maturation of B-lymphocytes into IgE-producing plasma cells [18, 19].
While the enzymatic machinery necessary for eicosanoid biosynthesis (COX-1 and COX-2,
prostaglandin synthases, thromboxane synthase, 5LOX, 15LOX, P450 mono-oxygenase) and
the eicosanoid receptors (PGE2 receptors (EP), thromboxane receptor, leukotriene B4 recep-
tors (BLT1 and BLT2)) are expressed in the thymus [20–32], little is known regarding the ei-
cosanoids present in the thymus through different stages of thymocyte maturation.

More than 90% of the thymocytes retrieved in the thymus are synchronized as DN on day
15.5 of the mouse embryonic development (E15.5). Thymocyte maturation then progresses,
and 70–80% of the thymocytes examined on embryonic day 18.5 are then DP. Fetal thymic
organ cultures (FTOC) are therefore frequently utilized to study the impact of gene ablation or
protein inhibition on thymocyte development [33, 34]. FTOCs were previously used to assess
the contribution of prostanoids in the thymus [21, 35]. In a first study, which included fetal
thymuses isolated from COX-1 and COX-2 knockout (KO) mice and inhibitors of COX-1 and
COX-2, COX-1-dependent PGE2 production was shown involved in the transition from DN to
DP T-cells whereas the COX-2-dependent PGE2 production was shown involved in the transition from DN to
DP T-cells whereas the COX-2-dependent PGE2 production was shown necessary in genera-
tion of CD4+ SP T-cells. Furthermore, using specific agonists of prostanoid receptors, it was
confirmed that these effects were mediated through activation of the PGE2 receptors EP-2 and
EP-1. Taken together, these observations point to an important role of AA metabolites, most
specifically PGE2, in T-cell development in the thymus. However, a second study showed that
the maturation of thymocytes remained intact in culture of fetal thymuses isolated from mice
deficient in COX-1, COX-2, EP-1, EP-2 and mice deficient for both COX-1 and COX-2 [35].
While the addition of a COX-2 inhibitor (NS-398) to thymic cultures reduced the formation of
CD4+ T-cells, this effect was unspecific as it was also present in FTOCs from COX-2 deficient
mice and it was not reversed by the exogenous addition of PGE2 (up to 10μM) [35]. Thus, whether prostanoids actually participate in thymocyte development remains unclear.

AA, which is mainly esterified at the sn-2 position of phospholipids, has to be released from the membrane phospholipids to be metabolized into eicosanoids. The availability of AA is thus a rate-limiting step for the production of eicosanoids [36]. Phospholipases A2 (PLA2) catalyze the hydrolysis of phospholipids in sn-2, generating free fatty acids and lysophospholipids [37]. So far, more than 20 mammalian PLA2s have been described. The PLA2 repertoire includes; 1) the secreted PLA2s (dependent of calcium), 2) the intracellular PLA2s of group VI independent of calcium, 3) the intracellular PLA2s of group IV dependent of calcium (with the exception of the group IVC (cPLA2 gamma), which does not rely on calcium for its activity), 4) the lysosomal PLA2, 5) the adipose-specific PLA2 and 6) the platelet-activating factor acetylhydrolases. The most studied and best-described PLA2 is the cytosolic PLA2 of group IVA, also called cPLA2α. This enzyme is ubiquitously expressed in mammalian cells, and cPLA2α gene ablation in mice showed its critical role in fertility, particularly in fetus implantation and labor [38, 39]. Importantly, the exogenous injection of PGE2 and of a stable analog of PGI2 (carbaprostacyclin) restored normal implantation in cPLA2α deficient mice [40], further supporting the notion of functional coupling between cPLA2α and prostaglandins. In concurrent studies, the function of cPLA2α in eicosanoid production in a context of inflammation is also exemplified, as cPLA2α deficient mice were resistant to experimental asthma, and the macrophages isolated from these mice failed to produce PGE2, platelet activating factor, leukotriene B4 and leukotriene C4 [38, 39]. A series of subsequent studies confirmed a dominant role of cPLA2α in eicosanoid production in several processes, including immunity, reproduction, inflammation and cancer [7, 37–45]. While cPLA2α is expressed in thymocytes [46], whether it plays a role in eicosanoid generation and thymocyte maturation is unknown.

For this study, we portrayed the eicosanoids produced in the thymus at different stages of thymocyte maturation and considered the potential role of cPLA2α in this process. As the role of eicosanoids in the thymus has been invoked, we further hypothesized that cPLA2α might contribute to thymocyte maturation. We found that the production of eicosanoids is modulated accordingly to the maturation of thymocytes, and that the production of eicosanoids and thymocytes can proceed independently of cPLA2α.

Materials and Methods

Ethic statement

This study was reviewed and approved by our institutional review board (Comité Éthique de la Recherche du CHU de Québec) before the study began.

Human thymuses from newborns and young children were obtained under an approved institutional review board protocol (Comité Éthique de la Recherche du CHU de Québec) following written consent of the parents after a cardiac surgery (CHU de Quebec). This consent procedure was approved by the Comité Éthique de la Recherche du CHU de Québec.

In this study, Guidelines of the Canadian Council on Animal Care were followed in a protocol approved by the Animal Welfare committee at Laval University (Quebec City, Canada) and all efforts were made to minimize suffering. Fetal thymus harvesting was performed after euthanasia of fetuses on ice. Adult thymuses were obtained after an isoflurane anesthesia followed by euthanasia with CO2.

Mice and genotyping

C57BL/6J mice were obtained from The Jackson Laboratory. cPLA2α deficient mice [38] were backcrossed up to the tenth generation in C57BL6/J background. The reproduction of cPLA2α
deficient mice was maintained by crossing heterozygous males and females, and the littermate cPLA$_2$α wild type (WT) and cPLA$_2$α KO were used for our experiments. The identification of cPLA$_2$α genotypes was performed using DNA isolated from mouse tail. The tails were digested with DirectPCR Lysis Reagent (Tail) (Viagen Biotech) and Proteinase K (Invitrogen) according to the manufacturer protocol and PCR amplification was performed using HotStarTaq DNA Polymerase (Qiagen) and the following primers: cPLA$_2$α forward (5’- TTCTCTTGGTTGATGAAGGC-3’), cPLA$_2$α reverse 5’-AAACTGACTGTAGCATCACAC-3’), NeoForward (cPLA$_2$α KO) (5’-ATGCCTTCTTGGAGAGTTC-3’). The following PCR steps were used: 15 minutes at 95°C, 35 cycles of 45 seconds at 94°C, 60 seconds at 65°C and 60 seconds at 72°C and the final step is 10 minutes at 72°C. The PCR products were then separated on 1.5% agarose gel containing ethidium bromide. The WT and KO products were distinguished by visualization of bands at 224 and 570 bp, respectively.

**Fetal Thymic Organ Culture**

FTOCs were produced as previously described [33, 34]. In brief, fecundation was timed from the first day of plug observation (day 0.5). Mouse fetuses were harvested from timed pregnant mice on gestational day 15.5. The fetal thymuses were cultured on 0.8μm Isopore Membrane filters (Millipores) placed on the surface of 12 well plates containing RPMI 1640 (Wisent) supplemented with 10% FBS for mouse myeloid colony forming cells (Stemcell Technologies), 1% penicillin/streptomycin (Wisent), 1% L-glutamine (Wisent) and 1% of 2-mercaptoethanol (Gibco). FTOC were fed daily by complete medium replacement with solvent control (DMSO or ethanol) or the following compounds: cPLA$_2$α inhibitor pyrrophenone (Cayman Chemical), arachidonic acid (Nu Chek Prep) and prostaglandin E$_2$ (Cayman Chemical). Fetal thymuses were cultured for 5 days at 37°C with 5% CO$_2$.

**Human thymus**

Small sections of human thymuses (≈ 2mm$^3$) were cultured as already described for mouse FTOCs. The human FTOCs-like were fed daily by complete medium replacement with solvent control (DMSO) or pyrrophenone (Cayman Chemical) for 5 days at 37°C with 5% CO$_2$.

**Flow cytometry analysis**

Thymuses were mechanically dissociated into single cell suspensions in PBS. The absolute cell number present in each thymus was determined by cell counting and labeling with fluorochrome-conjugated antibodies was performed according to the manufacturer protocols. The following antibodies were used: PE-Cy7 Hamster Anti-Mouse CD3ε (145-2C11), PE Rat Anti-Mouse CD4 (RM4-5), APC Rat Anti-mouse CD8a (53–6.7), PE-Cy7 mouse Anti-Human CD3 (clone SK7), PE mouse Anti-human CD4 (RPA-T4) and APC mouse Anti-Human CD8 (RPA-T8). All antibodies and their related isotype controls were purchased from BD Biosciences. Flow cytometry analysis was performed on a BD FACSCanto II Flow cytometer (BD Biosciences, San Jose, California, USA) and analyzed using FlowJo software (Ashland, Oregon USA).

**Mass spectrometry analysis of eicosanoids**

Eicosanoids from 1ml FTOC supernatants and crushed mouse adult thymuses were analyzed by combined liquid chromatography/tandem mass spectrometry, as already described [47]. The FTOC supernatants were collected daily and conserved at -80°C before analysis. Thymuses from cPLA$_2$α WT and KO adult mice were crushed in 1ml PBS 1X and conserved at -80°C before analysis. Culture media (in absence of FTOC) was used as negative control for our
analyses. Deuterium standards purchased from Cayman Chemical were used to detect the set of eicosanoids listed in the Table 1.

**RT-QPCR**

Total RNA was extracted from C57BL6/J mouse thymus using TRIzol reagent (Invitrogen). All RNA samples were treated with DNase I to eliminate residual genomic DNA prior to

| Eicosanoids       | FTOC Detection | Adult thymus Detection |
|-------------------|----------------|-------------------------|
| LTB₄ products     | Detected       | Detected                |
| LTC₄              | Not detected   | Not detected            |
| LTD₄              | Not detected   | Not detected            |
| LTE₄              | Not detected   | Not detected            |
| 5-HETE            | Not detected   | Detected                |
| 8-HETE            | Not detected   | Not detected            |
| 11-HETE           | Detected       | Detected                |
| 12-HETE           | Not detected   | Detected                |
| Tetranor-12-HETE  | Not detected   | Not detected            |
| 15-HETE           | Not detected   | Detected                |
| 5-OxoETE          | Detected       | Detected                |
| 15-OxoETE         | Not detected   | Detected                |
| 5,6-DIHETE        | Detected       | Detected                |
| 5,15-DIHETE       | Detected       | Detected                |
| Resolvin D1       | Detected       | Detected                |
| Resolvin D2       | Not detected   | Not detected            |
| Resolvin E1       | Not detected   | Not detected            |
| 5,6-LXA₄          | Detected       | Detected                |
| 5,14-LXB₄         | Detected       | Detected                |
| PGD₂              | Not detected   | Detected                |
| PGE₂              | Detected       | Detected                |
| PGF₂α             | Detected       | Detected                |
| 11β-PGF₂α         | Not detected   | Not detected            |
| 2,3-Dinor-11β-PGF₂α| Not detected  | Not detected            |
| 6-Keto PGF₂α      | Detected       | Detected                |
| 2,3-Dinor-6-Keto PGF₂α| Detected | Detected               |
| TXB₂              | Detected       | Detected                |
| 2,3-Dinor TXB₂    | Detected       | Detected                |
| 11-dehydro TXB₂   | Not detected   | Not detected            |
| 12-HHTrE          | Detected       | Detected                |
| 8,9-DHET          | Detected       | Detected                |
| 11,12-DHET        | Not detected   | Not detected            |
| 14,15-DHET        | Detected       | Detected                |

Eicosanoids* from FTOC supernatants and adult mouse thymuses were measured by combined liquid chromatography/tandem mass spectrometry.

* Leukotriene (LT); Hydroxyeicosatetraenoic acid (HETE); Oxo-eicosatetraenoic acid (OxoETE); Dihydroxy-eicosatetraenoic acid (DiHETE); Lipoxin (LX); Prostaglandin (PG); Thromboxane (TXB); Hydroxy-heptadecatrienoic acid (HHTrE); Dihydroxy-eicosatrienoic acid (DHET).

doi:10.1371/journal.pone.0126204.t001
amplification. cDNA was synthesized using MLV-RT (invitrogen), real time quantitative PCR analysis was performed using a Rotorgene apparatus (Montreal Biotech, Canada) and levels of cPLA2α mRNA were determined using SYBR Green dye (Invitrogen) and the following primer pair: cPLA2 α forward (5’-CAGCTCTCAGGATTCCTTCGA-3’), cPLA2α reverse (5’-TCATA TATTCGTTC AAATTCATCTGGAT-3’), ribo S15 foward (5’-ATGTCTCT ATGACCACT GATGCA-3’), ribo S15 reverse (5’-GCCGAGACCAGGTTCA-3’). The relative expression of the cPLA2α gene was determined using the 2−ΔΔCT methods. In brief the ΔCt is cPLA2α Ct—ribo S15 Ct.

Statistical analyses
All data are presented as mean ± SEM. Statistical significance between 2 groups was determined using unpaired Student t tests. All the statistical analyses were performed using Prism software 4.00 (GraphPad Software, CA, USA).

Results
Eicosanoid profiling during thymocyte maturation
To determine the eicosanoids produced by the thymus through different stages of thymocyte maturation, we compared the lipid profile generated in FTOC supernatants (E15.5) after 1, 3 and 5 days of culture. The full-set of eicosanoids that was evaluated is presented in Table 1. LTC4, LTD4, LTE4, 8-HETE, Tetranor-12-HETE, Resolvin D2, Resolvin E1, 11α-PGF2α, 2,3-Dinor-11β-PGF2α, 11-dehydro TXB2 and 11,12-DHET were undetectable in FTOC supernatants and adult mouse thymuses. Furthermore, we found profound changes in the eicosanoid expression profile during the course of thymocyte maturation, with LTB4 and LXA4 representing the majority (>50%) of the eicosanoids expressed through the first 3 days of culture (Fig 1A and 1B, left and middle panel). At day 5 of culture, 14,15-DHET was the second most abundant lipid mediator produced by FTOCs after LTB4, while LXA4 appeared essentially absent (Fig 1A and 1B, right panel). Next, we wished to verify the expression of eicosanoids present in the thymus of adult mice (6–8 weeks). In this case, we found that LTB4 remains among the most abundant lipid mediator present in the thymus, followed by LXA4 and 5-HETE (Fig 1C).

The production of eicosanoids by FTOCs, adult thymus and the modulation of their production during the course of thymocyte development, prompted our examination of the role of cPLA2α. Using FTOCs and adult thymuses from cPLA2α deficient mice, we observed that the majority of the most abundant eicosanoids could be produced independently of the expression of cPLA2α (Fig 1B and 1C). The ablation of the gene coding for cPLA2α led to the absence of 5,15-DiHETE, 5,14-LXB4 and TXB2 at day 1, of 2,3-Dinor TXB2, 2,3-Dinor-6-Keto PGF2α and 5,15-DiHETE at day 3 and of 14,15-DHET and 5-OxoETE at day 5 of culture in FTOCs, suggesting that cPLA2α is implicated in the generation of these lipids (Fig 1B). Furthermore, 14,15-DHET at day 1, 14,15-DHET and 11-HETE at day 3, 8,9-DHET, 5,6-LXA4 and 5,6-DiHETE at day 5 were only detected in cPLA2α KO FTOC supernatants (Fig 1B) while significantly more Resolvin D1 was observed in absence of cPLA2α in mouse adult thymuses (Fig 1C), suggesting that cPLA2α expression can also negatively regulate the production of some eicosanoids. Taken together, these results demonstrate that the production of eicosanoids is modulated accordingly to the development stages of thymocytes, and that the majority of the eicosanoids detected in mouse fetal and adult thymuses are produced independently of cPLA2α. These observations also point to a contribution of cPLA2α in expression of a subset of less abundant eicosanoids in the thymus.
The disruption of the cPLA₂α gene does not affect the maturation of thymocytes in FTOC

Although cPLA₂α appeared dispensable for the biosynthesis of most eicosanoids, subtle changes in the lipid expression profile in the thymus were observed in absence of cPLA₂α. Furthermore, cPLA₂α might be implicated in the generation of eicosanoids in discrete cellular lineages in the thymus, which might not be possible to estimate when measuring the complete pool of eicosanoids produced by the entire organ. We thus wished to verify whether the cPLA₂α is implicated in thymocyte maturation, and we firstly used a genetic approach in FTOCs [33, 34]. The thymocytes present in the cultured thymus from cPLA₂α WT and KO littermate mice were examined cytofluorometrically, and no differences in their maturation were observed. Indeed, the four subpopulations studied, the DN (CD3⁺/CD4⁻/CD8⁻), the DP
(CD3+/CD4+/CD8+) and the SP (CD3+/CD4-/CD8+) thymocytes showed the same repartition in the cPLA2α WT and KO FTOCs (Fig 2A and 2B). In light of these results, cPLA2α is dispensable for the maturation of thymocytes in mice.

Evaluation of the impact of the cPLA2α inhibitor pyrrophenone on thymocyte maturation

We next used a pharmacological approach to confirm our observations made in genetically engineered mice. The cPLA2α inhibitor pyrrophenone (PP) [48] suppresses AA release from an activated monocytic cell line and PGE2 release by renal mesangial cells with an IC50 of 24nM.

---

**Fig 2.** The disruption of the cPLA2α gene does not impact thymocyte maturation in FTOC. A. Representative thymocyte subpopulation distribution in WT and KO cPLA2α FTOC. After 5 days of culture, the identification of thymocytes with fluorochrome-conjugated antibodies directed against CD3, CD4 and CD8 was determined by flow cytometry. B. WT and KO cPLA2α fetal thymuses were cultured during 5 days as FTOCs. After mechanical dissociation of fetal thymuses, the thymocytes were labeled with fluorochrome-conjugated antibodies directed against CD3, CD4, and CD8, and analyzed by flow cytometry. Data are mean ± SEM of 6 independent experiments and the number of fetal thymuses for each genotype is: cPLA2α+/+(n = 17); cPLA2α−/−(n = 9). NS (non significant).

doi:10.1371/journal.pone.0126204.g002
and 8nM, respectively [48]. WT FTOCs were cultured during 5 days in absence or in presence of indicated concentrations of PP. Thymocytes were identified with fluorochrome-conjugated antibodies directed against CD3, CD4 and CD8 by flow cytometry. As for the genetic approach, cPLA2α appeared dispensable, as no differences were observed in the maturation of thymocytes in presence of PP compared to those left untreated (Fig 3A and 3B). Rocca et al. and Xu et al. observed that the culture to FTOCs in presence of high concentrations (40 μM) of the COX-2 inhibitor NS-398 led to the blockade of thymocyte differentiation [21, 35]. This effect of NS-398 was considered unspecific, as it was recapitulated in COX-2 deficient FTOCs and it was not reversed by the addition of PGE2 [35]. Using high concentrations (1μM) of the cPLA2α inhibitor, we observed an increase and a decrease of DN and DP thymocyte populations, respectively (Fig 4A and 4B). Furthermore, we observed an increase of the two SP populations (Fig 4A and 4B). Thus, high dose of PP affects the maturation of mouse thymocytes. We next wished to confirm the specificity of the inhibitor, here using cPLA2α KO FTOCs. We observed that PP, used at 1 μM, impedes the maturation of

Fig 3. Pharmacological blockade of cPLA2α does not affect thymocyte maturation in FTOC. A. Representative thymocyte subpopulation distribution in WT cPLA2α FTOC after 5 days of culture in absence or presence of indicated concentrations of PP. Thymocytes were identified with fluorochrome-conjugated antibodies directed against CD3, CD4 and CD8 by flow cytometry. B. WT cPLA2α fetal thymuses were cultured during 5 days as FTOCs in absence or presence of indicated concentrations of PP. After mechanical dissociation of fetal thymuses, the thymocytes were labeled with fluorochrome-conjugated antibodies directed against CD3, CD4, and CD8 and analyzed by flow cytometry. Data are mean ± SEM of 5 independent experiments and the number of fetal thymuses for each condition is: Diluent (n = 10); 10nM PP (n = 8); 100nM PP (n = 12). NS (non significant).

doi:10.1371/journal.pone.0126204.g003
thymocytes deficient in cPLA2α (Fig 5A and 5B). Furthermore, the exogenous addition of AA and of PGE2, which was reported involved in thymocyte maturation [21], to PP-treated FTOCs did not restore normal thymocyte maturation (Fig 6A and 6B). Taken together, these results demonstrate that high doses of PP inhibit thymocyte maturation through the inhibition of another target than cPLA2α, most likely irrelevant to AA and prostaglandin release.

cPLA2α gene disruption does not impact thymocyte maturation in the adult mouse

Prior studies evaluated the role of prostaglandins in thymocyte maturation in the adult [21]. Having confirmed that cPLA2α is dispensable in thymocyte maturation at a fetal development
stage in mice, we thus verified whether cPLA2α might be involved in thymocyte maturation in adult mice. The different thymocyte subsets were determined in cPLA2α WT and cPLA2α KO thymuses from adult (6–8 weeks) littermate mice. No differences in the proportions of the
Fig 6. The unspecific effect of PP on thymocyte maturation is not reversed by exogenous AA and PGE₂.

A. Representative thymocyte subpopulation distribution in WT cPLA₂α FTOC after 5 days of culture in absence or presence of 1μM of PP and exogenous (1μM) AA and PGE₂. Thymocytes were identified cytfluorometrically using fluorochrome-conjugated antibodies directed against CD3, CD4 and CD8.

B. WT cPLA₂α fetal thymuses were cultured during 5 days as FTOCs in absence or presence of 1μM of PP, and exogenous (1μM) AA and PGE₂. After mechanical dissociation of fetal thymuses, the thymocytes were identified with fluorochrome-conjugated antibodies directed against CD3, CD4, and CD8 and analyzed by flow cytometry. Data are mean ± SEM of 3 independent experiments and the number of fetal thymuses for each condition is: Diluent (n = 5); 1μM PP (n = 6); 1μM PP and 1μM AA (n = 5); 1μM PP and 1μM PGE₂ (n = 5). * P<.05; ** P<.01; *** P<.001.

doi:10.1371/journal.pone.0126204.g006
thymocyte subpopulations were observed between WT and KO thymuses (Fig 7A and 7B). Thus, the cPLA$_2$$^\alpha$ is dispensable for normal thymocyte maturation in adult mice.

Pharmacological inhibition of cPLA$_2$$^\alpha$ does not impact human thymocyte maturation

Having demonstrated that the maturation of fetal and adult mouse thymocytes could proceed independently of cPLA$_2$$^\alpha$, we wished to confirm our observations using human thymocytes. For this, we used thymuses from human newborns and young children suffering of cardiac malformation and undergoing thymectomies.
To determine the role of the cPLA₂α in human thymocyte maturation, small sections of human thymuses were cultured in absence or in presence of different concentrations of PP and then the thymocyte subpopulations were determined cytofluorometrically. We observed no differences in the percentage of different thymocyte subsets (DN, DP, SP CD4⁺ and SP CD8⁺) when thymuses were treated with PP up to 1μM (Fig 8A and 8B). Thus, cPLA₂α appears dispensable for the maturation of human thymocytes.

Discussion

In this study, we reveal for the first time the elaborated set of eicosanoids produced by the thymus through different stages of thymocyte development. LTB₄ and LXA₄ were the most abundant eicosanoids found in thymus. LTB₄ is a recognized pro-inflammatory mediator involved in phagocyte chemotaxis, [49] while LXA₄ displays anti-inflammatory activities and mediates clearance of apoptotic cells [50, 51]. LTB₄ and LXA₄ might play roles in the thymus, such as the recruitment of phagocytes and the stimulation of apoptotic cell clearance. The actual role of these lipids in the thymus is worth investigating, especially when it is considered that 98% of the thymocytes die by apoptosis in the thymus [52, 53]. Furthermore, we showed that the eicosanoid expression profile is modulated through the different thymocyte maturation stages, pointing to tight regulation of enzymes implicated in eicosanoid generation in the thymus. Future studies are thus necessary to verify the role of eicosanoids in thymus and the regulation mechanisms behind their production.

Through its important role in eicosanoid production, cPLA₂α plays major roles in several physiological and pathophysiological processes, including immunity, reproduction, cancer and inflammation [7, 37–45]. Prostaglandins and their receptors are expressed in the thymus, and prior studies suggested that they are necessary for proper thymocyte maturation. Furthermore, it was demonstrated that the thymus is the organ with the highest concentration of thromboxané receptor, which is mostly expressed on DP thymocytes and appears implicated in the induction of thymocyte apoptosis [22] [25]. Herein, we surmised that cPLA₂α might participate in eicosanoid generation and thymocyte maturation. To our surprise, we observed that production of most abundant eicosanoids and thymocyte maturation in the thymus occur independently of cPLA₂α.

While cPLA₂α is expressed in thymocytes [46] and its mRNA expression is modulated throughout development (S1 Fig), the exact role of cPLA₂α in the thymus thus remains obscure. We investigated the impact of cPLA₂α on the major populations of thymocytes based on surface expression of CD3, CD4 and CD8 receptors. However, cPLA₂α and its products might have more subtle roles, and might regulate the development of other T-cell subpopulations such as T regs and γδ T-cells. Indeed, we showed that absence of cPLA₂α has an impact on some less abundant eicosanoids. Whether these eicosanoids, and thus the cPLA₂α, are involved in the function or development of scarce cellular populations is unknown. Furthermore, cPLA₂α might be implicated in the production of eicosanoids that both positively and negatively regulate maturation of thymocytes. Thus, the overall effects of cPLA₂α deficiency on thymocyte phenotype would be imperceptible. Finally, lysophosphatidic acid is involved in lymphocyte transmigration from the high endothelial venules of lymph nodes [54]. Whether cPLA₂α and its products are also implicated in processes such as thymocyte entry or egress is unknown. As cPLA₂α and AA metabolites are expressed in the thymus, the delineation of their exact role in the establishment of T-cell repertoire remains of great interest.

The prior demonstration of a role of prostaglandins in thymocyte maturation [21] was our impetus for our investigation of cPLA₂α in the thymus. However, the actual role of prostaglandins in thymocyte maturation is currently debated. Indeed, two distinct studies reported
Fig 8. cPLA$_2$$\alpha$ inhibition does not impact human thymocyte maturation. A. Representative thymocyte subpopulation distribution in human FTOC after 5 days of culture in absence or presence of indicated concentrations of PP. Thymocytes were identified cytofluorometrically using fluorochrome-conjugated antibodies directed against CD3, CD4 and CD8. B. Human FTOCs were cultured during 5 days in absence or presence of indicated concentrations of PP. After mechanical dissociation of human FTOCs, the thymocytes were labeled with fluorochrome-conjugated antibodies directed against CD3, CD4, and CD8 and analyzed by flow cytometry. Data are mean ± SEM of 3 independent experiments and the number of thymuses for each condition is: Diluent (n = 6); 10nM PP (n = 6); 100nM PP (n = 6); 1000nM PP (n = 6). NS (non significant).

doi:10.1371/journal.pone.0126204.g008
divergent results. Whereas a first study suggested that COX-1 and COX-2-derived PGE2 participate in thymocyte maturation [21], a second one described that mice lacking expression of COX-1 and COX-2, EP-1 and EP-2 display normal thymocyte maturation [35]. What explains the discrepancies between these two studies is unclear, but we speculate that specific housing animal facility environment or background genetic drift might have contributed. Our results cannot settle the debate. Indeed, cPLA2α is not the only PLA2 enzyme expressed in the thymus [55–57] and other enzymes might participate to prostaglandin production in its absence. Hence, PGE2 levels are not altered by the absence of cPLA2α in the thymus (Fig 1B and 1C). Furthermore, sPLA2 X, which is highly efficiently at releasing AA from the cellular outer leaflet, is also expressed in the thymus [55, 56, 58, 59]. As we also excluded sPLA2 X in thymocyte maturation (S2A and S2B Fig), other PLA2 and or lipases expressed in thymus [56, 57] might thus compensate the absence of the cPLA2α and sPLA2 X for the production of prostaglandins.

We further observed that high concentrations of the cPLA2α inhibitor PP impair thymocyte maturation in mice, but not in humans. Similarly to the observations made by Xu et al. using high concentrations of the COX-2 inhibitor NS-398, [35] we demonstrated that the effect of PP at high concentrations (around 125 time higher than the IC50) is independent of its ability to inhibit its specific target. It seems unplausible that the unspecific target(s) of NS-398 and PP are the same. Indeed, the two compounds are structurally highly different and the unspecific effects observed on thymocytes are also distinct. Given that PP has no impact on human thymocyte development, we suggest that its unspecific target expressed in mice has no human ortholog, or that the human ortholog has a much lower affinity for the inhibitor. An unspecific effect of PP has recently been reported in a distinct study [60]. The authors demonstrated that the release of AA and lactate dehydrogenase from cPLA2α KO fibroblasts was efficiently inhibited by PP through the prevention of mitochondrial calcium uptake. The inhibition of this process in FTOCs could explain the reduction in thymocyte maturation but remains to be established.

In sum, our study provides novel information concerning the broad repertoire of eicosanoids present in the thymus and on the role of cPLA2α in thymocyte development. As a plethora of molecules drive T-cell functions in lymphoid organs and in the periphery, our study adds to the comprehension of mechanisms that are key in immunity.

Supporting Information
S1 Fig. cPLA2α mRNA expression is modulated according to the development stage. Relative expression of cPLA2α mRNA in mouse thymuses at E15.5, E18.5, 4–6 weeks, 6 months (and older) of age was determined by RT-QPCR and $2^{-\Delta\Delta \text{Ct}}$ methods. Data are mean ± SEM of 3 independent experiments. (TIF)

S2 Fig. sPLA2 X gene disruption does not affect thymocyte maturation in FTOC. A. Representative thymocyte subpopulation distribution in WT and KO sPLA2 X FTOC after 5 days of culture. Thymocytes were identified by flow cytometry using fluorochrome-conjugated antibodies directed against CD3, CD4 and CD8. B. WT and KO sPLA2 X fetal thymuses were cultured during 5 days as FTOCs. After mechanical dissociation of fetal thymuses, thymocytes were labeled with fluorochrome-conjugated antibodies directed against CD3, CD4, and CD8 and analyzed by flow cytometry. Data are mean ± SEM of 4 independent experiments and the number of fetal thymuses for each genotype is: sPLA2 X+/+(n = 7); sPLA2 X−/−(n = 13). NS (non significant). (TIF)
Author Contributions
Conceived and designed the experiments: MR EB. Performed the experiments: MR GSN MHG EB. Analyzed the data: MR GSN MHG EB. Contributed reagents/materials/analysis tools: JP FJ MHG. Wrote the paper: MR GSN JP FJ MHG EB.

References
1. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005; 5(10):772–82. PMID:16200080
2. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol. 2006; 24:571–606. PMID:16491137
3. Takahama Y. Journey through the thymus: stromal guides for T-cell development and selection. Nat Rev Immunol. 2006; 6(2):127–35. PMID:16551260
4. Yarilin AA, Belyakov IM. Cytokines in the thymus: production and biological effects. Curr Med Chem. 2004; 11(4):447–64. PMID:14965226
5. Demeure CE, Yang LP, Desjardins C, Raynauld P, Delespesse G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur J Immunol. 1997; 27(12):3526–31. PMID:9468483
6. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 1991; 146(1):108–13. PMID:1845802
7. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012; 188(1):21–8. doi: 10.4049/jimmunol.1101029 PMID: 22187483
8. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med. 1995; 181(2):775–9. PMID: 7836930
9. Wang K, McDyer JF, Seder RA. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol. 1998; 161(6):2723–30. PMID: 9743329
10. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med. 2009; 15(6):633–40. doi: 10.1038/nm.1968 PMID: 19465928
11. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McClanahan TK, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009; 206(3):535–48. doi: 10.1084/jem.20082293 PMID: 1973625
12. Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P, Ferrari-Lacraz S, et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood. 2008; 112(9):3696–703. doi: 10.1182/blood-2008-05-155408 PMID: 18698005
13. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, Sallusto F. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur J Immunol. 2009; 39(5):1301–12. doi: 10.1002/eji.200838969 PMID: 19394872
14. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y, Tanaka S, et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol. 2005; 6(5):524–31. PMID: 15806106
15. Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Tasken K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol. 2008; 20(2):235–45. PMID: 18156149
16. Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol. 2006; 177(1):246–54. PMID: 16785520
17. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005; 65(12):5211–20. PMID: 15958566
18. Fedyk ER, Phipps RP. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci U S A. 1996; 93(20):10978–83. PMID: 8655294
19. Roper RL, Brown DM, Phipps RV. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J Immunol. 1995; 154(1):162–70. PMID: 7995935
20. Rocca B, Maggiano N, Habib A, Petrucci G, Gessi M, Fattorossi A, et al. Distinct expression of cyclooxygenase-1 and -2 in the human thymus. Eur J Immunol. 2002; 32(5):1482–92. PMID: 11981937
21. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest. 1999; 103(10):1469–77. PMID: 10330429

22. Namba T, Sugimoto Y, Hirata M, Hayashi Y, Honda A, Watabe A, et al. Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun. 1992; 184(3):1197–203. PMID: 1375456

23. Nusing R, Lesch R, Ullrich V. Immunohistochemical localization of thrombomaxane synthase in human tissues. Eicosanoids. 1990; 3(1):53–8. PMID: 1691652

24. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001; 108(1):15–23. PMID: 11435451

25. Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O, et al. Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med. 1993; 178(5):1825–30. PMID: 8228829

26. Honda A, Sugimoto Y, Namba T, Watabe A, Irie A, Negishi M, et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J Biol Chem. 1993; 268(11):7759–62. PMID: 8385118

27. Sugimoto Y, Namba T, Honda A, Hayashi Y, Negishi M, Ichikawa A, et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem. 1992; 267(10):6463–6. PMID: 1372661

28. Chuang SS, Helvig C, Taimi M, Ramshaw HA, Collop AH, Amad M, et al. CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids. J Biol Chem. 2004; 279(8):6305–14. PMID: 14660610

29. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997; 387(6633):620–4. PMID: 9177352

30. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000; 192(3):421–32. PMID: 10934230

31. Hostein I, Dorion-Bonnet F, Bloch B, Vaillier D, Juzan M, Gualde N. 5-Lipoxygenase gene expression in the thymus. Thymus. 1992; 20(2):101–8. PMID: 1519314

32. Grichenko OE, Pushin AC, Shaposhnikova VV, Levitman M, Korystov lu N. [Analysis of 15-lipoxygenase activity in irradiated thymocytes]. Izvestiia Akademii nauk Seriia biologicheskaia / Rossiiskaia akademii nauk. 2004;(5):1517–21. PMID: 15559127

33. Jenkinson EJ, Anderson G. Fetal thymic organ cultures. Curr Opin Immunol. 1994; 6(2):293–7. PMID: 8011212

34. Xu H, Izon DJ, Loftin C, Spain LM. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition. Cell Immunol. 2001; 214(2):184–93. PMID: 12088417

35. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem. 1986; 55:69–102. PMID: 3017195

36. Murakami M, Kudo I. Phospholipase A2. J Biochem. 2002; 131(3):285–92. PMID: 11872155

37. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, et al. Reduced fertility and post-ischaemic brain injury in mice deficient in cytosolic phospholipase A2alpha. Nature. 1997; 390(6660):622–5. PMID: 9403693

38. Miyaura C, Inada M, Matsumoto C, Ohshiba T, Shimizu T, et al. An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J Exp Med. 2003; 197(10):1303–10. PMID: 12743173
44. Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH, Wu T. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J Biol Chem. 2002; 277(36):33153–63. PMID: 12077117

45. Wu T, Han C, Lunz JG 3rd, Michalopoulos G, Shelhamer JH, Demetris AJ. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology. 2002; 36(2):363–73. PMID: 12143044

46. Gilbert JJ, Stewart A, Courtney CA, Fleming MC, Reid P, Jackson CG, et al. Antigen receptors on immature, but not mature, B and T cells are coupled to cytosolic phospholipase A2 activation: expression and activation of cytosolic phospholipase A2 correlate with lymphocyte maturation. J Immunol. 1996; 156(6):2054–61. PMID: 8690892

47. Bollinger JG, Thompson W, Lai Y, Oslund RC, Hallstrand TS, Sadilek M, et al. Improved sensitivity mass spectrometric detection of eicosanoids by charge reversal derivatization. Anal Chem. 2010; 82(16):6790–6. doi:10.1021/ac100720p PMID: 20704368

48. Ono T, Yamada K, Chikazawa Y, Ueno M, Nakamoto S, Okuno T, et al. Characterization of a novel inhibitor of cytosolic phospholipase A2alpha, pyrrophenone. Biochem J. 2002; 363(Pt 3):727–35. PMID: 11964173

49. Smith MJ, Ford-Hutchinson AW, Bray MA. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol. 1980; 32(7):517–8. PMID: 6105196

50. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Beralasconi G, et al. Lipoxins, aspirin-triggered epilipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol. 2002; 13(10):2497–507. PMID: 12239238

51. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol. 2000; 164(4):1663–7. PMID: 10657608

52. Shortman K, Egerton M, Spangrude GJ, Scollay R. The generation and fate of thymocytes. Semin Immunol. 1990; 2(1):3–12. PMID: 2129900

53. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature. 1994; 372(6591):100–3. PMID: 7969401

54. Bai Z, Cai L, Umemoto E, Takeda A, Tohya K, Komai Y, et al. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol. 2013; 190(5):2036–48. doi: 10.4049/jimmunol.1202025 PMID: 23365076

55. Cupillard L, Koumanov K, Mattei MG, Lazdunski M, Lambeau G. Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J Biol Chem. 1999; 274(25):15745–52. PMID: 9188469

56. Eerola LI, Surrel F, Nevalainen TJ, Gelb MH, Lambeau G, Laine VJ. Analysis of expression of secreted phospholipases A2 in mouse tissues at protein and mRNA levels. Biochim Biophys Acta. 2006; 1761(7):745–56. PMID: 16757211

57. Valentim E, Koduri RS, Scimeca JC, Carle G, Gelb MH, Lazdunski M, et al. Cloning and recombinant expression of a novel mouse-secreted phospholipase A2. J Biol Chem. 1999; 274(27):19152–60. PMID: 10383420

58. Bezantine S, Koduri RS, Valentim E, Murakami M, Kudo I, Ghomashchi F, et al. Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J Biol Chem. 2000; 275(5):3179–91. PMID: 10652303

59. Moriya Y, Saiga A, Yokota Y, Suzuki N, Ikeda M, Ono T, et al. Mouse group X secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor. Arch Biochem Biophys. 2000; 381(1):31–42. PMID: 11019817

60. Yun B, Lee H, Ghosh M, Cravatt BF, Hsu KL, Bonventre JV, et al. Serine hydrolase inhibitors block necrotic cell death by preventing calcium overload of the mitochondria and permeability transition pore formation. J Biol Chem. 2014; 289(3):1491–504. doi: 10.1074/jbc.M113.497651 PMID: 24297180